Clinical Trial Results:
A Study to Evaluate the Comparative Bioavailability of the Investigational Oral Pediatric Minitablet Formulation of MK-1439 Compared to the Adult Formulation of MK-1439 in Healthy Adult Subjects
Summary
|
|
EudraCT number |
2016-004728-48 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
27 Jun 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
08 Feb 2017
|
First version publication date |
08 Feb 2017
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
1439-043
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Merck Sharp & Dohme Corp.
|
||
Sponsor organisation address |
2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
|
||
Public contact |
Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
|
||
Scientific contact |
Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
Yes
|
||
EMA paediatric investigation plan number(s) |
EMEA-001676-PIP01-14 EMEA-001695-PIP01-14 | ||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 Jun 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
27 Jun 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
27 Jun 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of this trial is to evaluate the comparative bioavailability of a single-dose of the investigational oral pediatric mini-tablet formulation of MK-1439 (doravirine), 0.8 mg (100 mg total dose) compared to the adult formulation of doravirine tablets,100 mg in healthy adult males and females under fasted conditions.
|
||
Protection of trial subjects |
This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Jun 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United States: 24
|
||
Worldwide total number of subjects |
24
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
24
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
- | ||||||
Pre-assignment
|
|||||||
Screening details |
Healthy, non-tobacco using, adult male and females, 18-55 years of age were enrolled in this trial. | ||||||
Period 1
|
|||||||
Period 1 title |
Overall Study (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
All Randomized Participants | ||||||
Arm description |
- | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Adult Doravirine 100 mg x 1
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Following an overnight fast of at least 10 hours, a single doravirine adult formulation 100 mg tablet was administered orally.
|
||||||
Investigational medicinal product name |
Pediatric Doravirine 0.8 mg x 125
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Following an overnight fast of at least 10 hours, 125 doravirine oral pediatric formulation mini-tablets (equivalent to
100 mg) was administered orally.
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall Study
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Adult Doravirine 100 mg x 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Safety analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Following an overnight fast of at least 10 hours, a single doravirine adult formulation 100 mg tablet was administered orally.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Pediatric Doravirine 0.8 mg x 125
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Safety analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Following an overnight fast of at least 10 hours, 125 doravirine oral pediatric formulation 0.8 mg mini-tablets (equivalent to 100 mg) was administered orally.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
All Randomized Participants
|
||
Reporting group description |
- | ||
Subject analysis set title |
Adult Doravirine 100 mg x 1
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Following an overnight fast of at least 10 hours, a single doravirine adult formulation 100 mg tablet was administered orally.
|
||
Subject analysis set title |
Pediatric Doravirine 0.8 mg x 125
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Following an overnight fast of at least 10 hours, 125 doravirine oral pediatric formulation 0.8 mg mini-tablets (equivalent to 100 mg) was administered orally.
|
|
|||||||||||||
End point title |
Area under the concentration versus time curve from time 0-infinity (AUC0-∞) of doravirine | ||||||||||||
End point description |
Blood samples were collected at pre-dose and at intervals up to 72 hours after dosing in each period, and the plasma concentrations of doravirine were determined. Values were natural log-transformed before analysis and analyzed with a linear mixed effects model with fixed effects terms for treatment and period. An unstructured covariance matrix was used to allow for unequal treatment variances and to model the correlation between different treatment measurements within the same subject. The populations analyzed was all participants as treated during each treatment period.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24, 48, and 72 hours post-dose
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Ratio Pediatric/Adult tablet | ||||||||||||
Statistical analysis description |
Geometric Mean Ratio (GMR)
|
||||||||||||
Comparison groups |
Adult Doravirine 100 mg x 1 v Pediatric Doravirine 0.8 mg x 125
|
||||||||||||
Number of subjects included in analysis |
48
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [1] | ||||||||||||
Method |
|||||||||||||
Parameter type |
GMR | ||||||||||||
Point estimate |
0.73
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.68 | ||||||||||||
upper limit |
0.8 | ||||||||||||
Notes [1] - The number of participants in this analysis was not 48. As this was a crossover study, the 48 observations were from 24 participants. |
|
|||||||||||||
End point title |
Maximum concentration (Cmax) of doravirine | ||||||||||||
End point description |
Blood samples were collected at pre-dose and at intervals up to 72 hours after dosing in each period, and the plasma concentrations of doravirine were determined. Values were natural log-transformed before analysis and analyzed with a linear mixed effects model with fixed effects terms for treatment and period. An unstructured covariance matrix was used to allow for unequal treatment variances and to model the correlation between different treatment measurements within the same subject. The populations analyzed was all participants as treated during each treatment period.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 12, 24, 48, and 72 hours post-dose
|
||||||||||||
|
|||||||||||||
Notes [2] - One participant with a missing concentration value was not included in the analysis |
|||||||||||||
Statistical analysis title |
Ratio Pediatric/Adult tablet | ||||||||||||
Statistical analysis description |
GMR
|
||||||||||||
Comparison groups |
Adult Doravirine 100 mg x 1 v Pediatric Doravirine 0.8 mg x 125
|
||||||||||||
Number of subjects included in analysis |
47
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other [3] | ||||||||||||
Method |
|||||||||||||
Parameter type |
GMR | ||||||||||||
Point estimate |
0.53
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.47 | ||||||||||||
upper limit |
0.59 | ||||||||||||
Notes [3] - The number of participants in this analysis was not 47. As this was a crossover study, the 47 observations were from 24 participants. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From start of treatment on Day 1 up to Day 4 of each treatment period
|
||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
All participants as treated during each treatment period by the treatment received at the time of the event. As this was a crossover study, and each participant received more than one treatment, participants could be counted more than once.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
18.0
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Doravirine 100 mg x 1
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Following an overnight fast of at least 10 hours, a single doravirine adult formulation 100 mg tablet was administered orally. | ||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Doravirine 0.8 mg x 125
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Following an overnight fast of at least 10 hours, 125 doravirine oral pediatric formulation 0.8 mg mini-tablets (equivalent to 100 mg) was administered orally. | ||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
18 May 2015 |
Amendment 1: Included description of the size and the number of mini-tablets to be administered with dosing |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |